Low specificity of voltage-gated calcium channel antibodies in Lambert–Eaton myasthenic syndrome: a call for caution

[1]  D. Richman,et al.  3,4‐diaminopyridine base effectively treats the weakness of Lambert‐Eaton myasthenia , 2018, Muscle & nerve.

[2]  J. Probasco,et al.  Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results , 2017, Journal of Neurology.

[3]  B. Eymard,et al.  Lambert–Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer , 2017, Journal of Neurology.

[4]  M. Sharrock,et al.  Paraneoplastic autoantibody panels: sensitivity and specificity, a retrospective cohort , 2017, The International journal of neuroscience.

[5]  Luay Shayya,et al.  Clinical utility of seropositive voltage-gated potassium channel–complex antibody , 2016, Neurology. Clinical practice.

[6]  C. Klein,et al.  P/Q‐ and N‐type calcium‐channel antibodies: Oncological, neurological, and serological accompaniments , 2016, Muscle & nerve.

[7]  B. Schoser,et al.  Amifampridine phosphate (Firdapse®) is effective and safe in a phase 3 clinical trial in LEMS , 2016, Muscle & nerve.

[8]  Jeffrey A. Cohen,et al.  Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4‐diaminopyridine , 2016, Muscle & nerve.

[9]  Yuebing Li,et al.  Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center , 2015, Muscle & nerve.

[10]  J. Verschuuren,et al.  Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies , 2011, The Lancet Neurology.

[11]  Y. Hatanaka,et al.  3,4‐Diaminopyridine is more effective than placebo in a randomized, double‐blind, cross‐over drug study in LEMS , 2009, Muscle & nerve.

[12]  P. Wirtz,et al.  Efficacy of 3,4‐Diaminopyridine and Pyridostigmine in the Treatment of Lambert–Eaton Myasthenic Syndrome: A Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study , 2009, Clinical pharmacology and therapeutics.

[13]  M. Tsujihata,et al.  Seronegative Lambert-Eaton myasthenic syndrome , 2002, Neurology.

[14]  D. Sanders,et al.  Associations between circulating sex steroid hormones and cognition in normal elderly women , 2000, Neurology.

[15]  Jacqueline Palace,et al.  Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome , 1997, Journal of the Neurological Sciences.

[16]  P. O'Suilleabhain,et al.  Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. , 1995, The New England journal of medicine.

[17]  A. Vincent,et al.  An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[18]  A. Vincent,et al.  Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder , 1989, Trends in Neurosciences.

[19]  J. Daube,et al.  3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. , 1989, The New England journal of medicine.

[20]  N. Murray,et al.  AUTOIMMUNE AETIOLOGY FOR MYASTHENIC (EATON-LAMBERT) SYNDROME , 1981, The Lancet.

[21]  B. Eymard,et al.  Erratum to: Lambert–Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer , 2017, Journal of Neurology.